Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study
Part of paid clinical trials in Piscataway, New Jersey.
- Sponsor
- Rutgers, The State University of New Jersey
- Study ID
- NCT06745479
- Status
- Recruiting
Conditions
- Control Subjects
- Schizoaffective Disorder
- Schizophrenia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- Positive Emotion Upregulation — BEHAVIORALParticipants will identify personal goals or activities that they would like to engage in more and describe these goals/activities in a written format with research staff. Participants will then complete a gambling task during functional MRI scanning. Prior to making some gambling decisions, participants are instructed to mentally imagine achieving a goal or engaging in an enjoyable activity. Prior to the other decisions participants are instructed to respond naturally (i.e., not use the cognitive strategy).
Study Details
The goal of this clinical trial is to learn if attention and ways of thinking impact decision-making and brain processes related to decision-making in people with schizophrenia or schizoaffective disorder relative to people without either condition. It will also learn how brain functioning during decision-making relates to real-world decisions made during daily life. The main questions it aims to answer are: * Does paying attention to specific information impact decision-making and brain processes? * Does thinking in a certain way according to specific 'thinking strategies' improve brain processes related to decision-making? * Does brain functioning during decision-making relate to real-world choices to engage in activities? Researchers will compare brain functioning and decision-making on computer tasks of gambling after participants have been trained to use a positive thinking strategy. They will compare what is different in the brain and behavior when participants use this strategy and when they do not. Participants will also answer brief surveys about activities and feelings for a week in their daily lives. Participants will: * Complete several hours of clinical interviewing, cognitive tests, and surveys of about symptoms, experiences, and personality * Complete computer tasks about gambling decisions during MRI brain scanning and while having their visual attention measured using eye-tracking * Complete brief surveys about their activities and feelings 5 times a day for 1 week using a cell phone. Each survey only take several minutes.
Key Dates
- Start date
- Jan 7, 2025
- Status verified
- Mar 2026
- Primary completion
- Apr 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 74 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Single ArmThere is only 1 arm in this study. In this arm of the study, participants are instructed to implement a cognitive strategy (i.e., way of thinking) during 1/2 of the trials of a behavioral, gambling task. On the other 1/2 of the trials they behave naturally without implementing the cognitive strategy.
Primary Outcome Measure
Nucleus Accumbens Brain Activation [ Time Frame: Single timeframe during 1.5 hours of MRI scanning and behavioral task completion. ]
Central Contacts
- Pariya Chanthasensack, BS732-235-6438
- John Purcell, PhD732-235-6438
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Center for Advanced Human Brain Imaging Research | Piscataway | New Jersey | 08854 | David H Zald, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Piscataway, NJ
Related Studies
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPHASE3 · Recruiting · Alkermes, Inc. · Dothan, Alabama
- An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaPHASE3 · Recruiting · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Phoenix, Arizona
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaPHASE3 · Recruiting · Otsuka Pharmaceutical Development & Commercialization, Inc. · Bentonville, Arkansas
- Randomized Withdrawal Study in Patients With SchizophreniaPHASE3 · Recruiting · Vanda Pharmaceuticals · Rogers, Arkansas